Acute Myeloid Leukemia (Acute Myelogenous Leukemia)

Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Also Known As:
Acute Myelogenous Leukemia; Acute Myeloblastic Leukemia; Myelogenous Leukemia, Acute; Acute Myelocytic Leukemia; Acute Nonlymphocytic Leukemia; Leukemia, Myeloid, Acute; ANLL; Acute Myeloid Leukemia with Maturation; Acute Myeloid Leukemia without Maturation; Leukemia, Myeloblastic, Acute; Leukemia, Myelocytic, Acute; Leukemia, Myeloid, Acute, M1; Leukemia, Myeloid, Acute, M2; Leukemia, Nonlymphoblastic, Acute; Myeloblastic Leukemia, Acute; Myelocytic Leukemia, Acute; Myeloid Leukemia, Acute, M1; Myeloid Leukemia, Acute, M2; Nonlymphoblastic Leukemia, Acute; Acute Myeloblastic Leukemias; Acute Myelocytic Leukemias; Acute Myelogenous Leukemias; Acute Myeloid Leukemias; Acute Nonlymphoblastic Leukemia; Acute Nonlymphoblastic Leukemias; Acute Nonlymphocytic Leukemias; Leukemia, Acute Myeloblastic; Leukemia, Acute Myelocytic; Leukemia, Acute Myelogenous; Leukemia, Acute Myeloid; Leukemia, Acute Nonlymphoblastic; Leukemia, Acute Nonlymphocytic; Leukemias, Acute Myeloblastic; Leukemias, Acute Myelocytic; Leukemias, Acute Myelogenous; Leukemias, Acute Myeloid; Leukemias, Acute Nonlymphoblastic; Leukemias, Acute Nonlymphocytic; Myeloblastic Leukemias, Acute; Myelocytic Leukemias, Acute; Myelogenous Leukemias, Acute; Myeloid Leukemias, Acute; Nonlymphoblastic Leukemias, Acute; Nonlymphocytic Leukemias, Acute; Leukemia, Myelogenous, Acute; Leukemia, Nonlymphocytic, Acute; Myeloid Leukemia, Acute; Nonlymphocytic Leukemia, Acute
Networked: 14185 relevant articles (1624 outcomes, 1882 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Leukemia
2. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
3. Myelodysplastic Syndromes (Myelodysplastic Syndrome)
4. Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
5. BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)


1. Kantarjian, Hagop: 114 articles (09/2015 - 01/2002)
2. Marcucci, Guido: 92 articles (11/2015 - 09/2003)
3. Ravandi, Farhad: 88 articles (11/2015 - 02/2004)
4. Cortes, Jorge: 82 articles (09/2015 - 08/2002)
5. Garcia-Manero, Guillermo: 77 articles (12/2015 - 01/2002)
6. Faderl, Stefan: 76 articles (07/2015 - 08/2002)
7. Andreeff, Michael: 71 articles (07/2015 - 01/2002)
8. Appelbaum, Frederick R: 64 articles (08/2015 - 01/2002)
9. Berdel, Wolfgang E: 59 articles (09/2015 - 02/2002)
10. Bloomfield, Clara D: 59 articles (04/2014 - 08/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Acute Myeloid Leukemia:
1. Cytarabine (Cytosar-U)FDA LinkGeneric
2. Daunorubicin (Cerubidine)FDA LinkGeneric
3. Cyclophosphamide (Cytoxan)FDA LinkGeneric
4. Etoposide (VP 16)FDA LinkGeneric
5. Granulocyte Colony-Stimulating Factor (G-CSF)IBA
6. fludarabineIBA
7. Mitoxantrone (Novantrone)FDA LinkGeneric
8. Interleukin-2 (IL2)IBA
9. Busulfan (Busulfex)FDA Link
10. gemtuzumab (gemtuzumab ozogamicin)FDA Link

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Bone Marrow Transplantation (Transplantation, Bone Marrow)
3. Transplants (Transplant)
08/20/2009 - "In acute myelocytic leukemia (AML), for patients who receive transplants during first complete remission (CR1), no prospective randomized study has compared relapse incidence (RI) to cell source. "
05/01/2015 - "This retrospective study considered the outcomes of 181 patients with acute myeloid leukemia (AML) transplanted in second complete remission (CR2) between January 2005 and April 2012 and who received either a myeloablative autologous stem cell transplant (Auto-SCT; n = 82; median age: 48 years; median follow-up: 45 months) or an umbilical cord blood (UCB) allogeneic SCT (n = 99, median age: 46 years; median follow-up: 36 months; conditioning regimens: myeloablative n = 21, reduced n = 78; single unit n = 37, double units n = 62). "
01/15/2015 - "Patients with acute myeloid leukemia (AML) in first relapse after initial Complete Remission (CR) lasting ≥1 month were stratified per the European Prognostic Index (EPI) into favorable, intermediate, and poor-risk groups based on duration of first CR, cytogenetics, age, and transplant history. "
02/01/2014 - "We analyzed 604 adults with acute myeloid leukemia in first complete remission (CR1) reported to the Center for International Blood and Marrow Transplant Research who received a reduced-intensity or nonmyeloablative conditioning HCT from an HLA-identical sibling, HLA-matched unrelated donor, or umbilical cord blood donor from 2000 to 2010. "
04/01/2010 - "Acute myeloid leukemia: when to transplant in first complete remission."
4. Transplantation (Transplant Recipients)
5. Stem Cell Transplantation